Short-Course Palliative RT Cuts Cancer Pain

“Short-course palliative radiotherapy provided pain relief equivalent to that of conventional protocols, and allowed patients with advanced cancer to spend more time at home, investigators reported.

“Half as many patients underwent more than five treatment sessions and hospital length of stay decreased by 50% following implementation of a palliative radiation oncology service. At the same time, significantly more patients completed the planned course of radiotherapy, which resulted in a trend toward better pain relief.”


Sativex No Better than Placebo for Cancer Pain in Trial, but Manufacturers Still Hopeful

The gist: A cancer pain drug called Sativex was not found to be any better than a placebo in a recent clinical trial. However, the makers of the drug are still optimistic about it, based on previous successful studies. They will continue to test it to see whether they can get better results.

“GW Pharmaceuticals plc and Otsuka Pharmaceutical Development & Commercialization, Inc., have reported the top-line results from the first of three Phase 3 trials for the investigational product Sativex in the treatment of pain in patients with advanced cancer who experience inadequate analgesia during optimized chronic opioid therapy. In this first trial, Sativex (as adjunctive treatment to optimized chronic opioid therapy) did not meet the primary endpoint of demonstrating a statistically significant difference from placebo.

” ‘Although we missed the primary endpoint in this trial, based upon the positive data seen in the Phase 2 program, we remain confident in the ability for Sativex to relieve cancer pain in this patient population’, stated Justin Gover, GW’s Chief Executive Officer. ‘We have two additional pivotal Phase 3 trials ongoing which, if positive, would still allow us to submit a New Drug Application with the US FDA. We look forward to results from these two further studies later this year.’ “


Exercise Eases Arthralgia Caused by Aromatase Inhibitors

“Exercise helps relieve aromatase inhibitor (AI)-induced pain in breast cancer survivors, according to research published online Dec. 1 in the Journal of Clinical Oncology.

“Melinda L. Irwin, Ph.D., M.P.H., of the Yale School of Public Health in New Haven, Conn., and colleagues randomly assigned breast cancer patients receiving an AI who reported arthralgia to either exercise (61 patients) or usual care (60 patients). Exercise consisted of 150 minutes per week of aerobic exercise and twice-weekly supervised strength training.

“The researchers found that, at 12 months, worst joint pain scores decreased by 1.6 points (29 percent) in the exercise group and increased by 0.2 points in the usual-care group (P pain scores also were observed in the exercise group compared with the usual-care group.”


Study Shows Integrative Medicine Relieves Pain and Anxiety for Cancer Inpatients

“Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.

“The Penny George Institute for Health and Healing researchers found that therapies can substantially decrease pain and anxiety for hospitalized . Their findings are published in the current issue of the Journal of the National Cancer Institute Monographs.

” ‘Following Integrative medicine interventions, such as medical massage, acupuncture, guided imagery or relaxation response intervention, patients experienced a reduction in pain by an average of 47 percent and anxiety by 56 percent,’ said Jill Johnson, Ph.D., M.P.H., lead author and Senior Scientific Advisor at the Penny George Institute.

” ‘The size of these reductions is clinically important, because theoretically, these therapies can be as effective as medications, which is the next step of our research,’ said Jeffery Dusek, Ph.D., senior author and Research Director for the Penny George Institute.”


Studies Show Exercise Therapy, Acupuncture Benefit Breast Cancer Survivors

“Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer hope for breast cancer survivors struggling with cancer-related pain and swelling, and point to ways to enhance muscular strength and body image. The studies appear in a first of its kind monograph from the Journal of the National Cancer Institute Monographs focusing on integrative oncology, which combines a variety of therapies, some non-traditional, for maximum benefit to cancer patients.

“In the first study, A Hybrid Effectiveness-Implementation Trial of an Evidence-Based Exercise Intervention for Breast Cancer Survivors, Penn researchers assessed patients participating in “Strength after Breast Cancer,” a Penn Medicine-developed, evidence-based exercise and education program for breast cancer survivors. The study was intended to investigate the ease and effectiveness of transporting a research-based treatment into a practice setting. The primary goal of the study was to demonstrate program effectiveness for patients after transition from research to a practice setting. The secondary goal was to understand the implementation process and identify barriers to implementation.”


Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting – San Francisco Business Times

“Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.

Data from six patients with advanced cancer and severe refractory pain, who received either 13 or 26 mcg injection of RTX into the intrathecal space, showed a clinically meaningful improvement in quality of life following the single injection.”


Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting – San Francisco Business Times

“Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.

Data from six patients with advanced cancer and severe refractory pain, who received either 13 or 26 mcg injection of RTX into the intrathecal space, showed a clinically meaningful improvement in quality of life following the single injection.”


Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting – San Francisco Business Times

“Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.

Data from six patients with advanced cancer and severe refractory pain, who received either 13 or 26 mcg injection of RTX into the intrathecal space, showed a clinically meaningful improvement in quality of life following the single injection.”